{"lastUpdatedAt": 1611085267730, "totalPosts": {"label": "Total Posts", "value": 97}, "totalComments": {"label": "Total Comments", "value": 829}, "postRate": {"title": "Post Rate", "data": [{"label": "2021-01-18T01:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T02:00:00.000+05:30", "value": 6}, {"label": "2021-01-18T03:00:00.000+05:30", "value": 3}, {"label": "2021-01-18T04:00:00.000+05:30", "value": 3}, {"label": "2021-01-18T06:00:00.000+05:30", "value": 2}, {"label": "2021-01-18T07:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T08:00:00.000+05:30", "value": 2}, {"label": "2021-01-18T09:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T10:00:00.000+05:30", "value": 2}, {"label": "2021-01-18T11:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T13:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T14:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T17:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T18:00:00.000+05:30", "value": 2}, {"label": "2021-01-18T19:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T20:00:00.000+05:30", "value": 3}, {"label": "2021-01-18T21:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T22:00:00.000+05:30", "value": 4}, {"label": "2021-01-18T23:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T00:00:00.000+05:30", "value": 6}, {"label": "2021-01-19T01:00:00.000+05:30", "value": 1}, {"label": "2021-01-19T02:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T03:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T04:00:00.000+05:30", "value": 4}, {"label": "2021-01-19T06:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T07:00:00.000+05:30", "value": 3}, {"label": "2021-01-19T08:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T09:00:00.000+05:30", "value": 3}, {"label": "2021-01-19T10:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T12:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T13:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T15:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T17:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T18:00:00.000+05:30", "value": 6}, {"label": "2021-01-19T19:00:00.000+05:30", "value": 5}, {"label": "2021-01-19T20:00:00.000+05:30", "value": 4}, {"label": "2021-01-19T21:00:00.000+05:30", "value": 4}, {"label": "2021-01-19T22:00:00.000+05:30", "value": 4}, {"label": "2021-01-19T23:00:00.000+05:30", "value": 1}]}, "commentRate": {"title": "Comment Rate", "data": [{"label": "2021-01-19T23:00:00.000+05:30", "value": 216}, {"label": "2021-01-20T00:00:00.000+05:30", "value": 527}, {"label": "2021-01-20T01:00:00.000+05:30", "value": 86}]}, "commentSentiments": {"title": "Comment Sentiments", "data": [{"name": "positive", "value": 345}, {"name": "neutral", "value": 337}, {"name": "negative", "value": 147}]}, "postSentiments": {"title": "Post Sentiments", "data": [{"name": "neutral", "value": 58}, {"name": "positive", "value": 32}, {"name": "negative", "value": 7}]}, "topStocks": {"title": "Top stocks", "data": [{"label": "SINT", "value": 2}, {"label": "PT", "value": 2}, {"label": "GEVO", "value": 2}, {"label": "CTRM", "value": 2}, {"label": "ATOS", "value": 2}, {"label": "TRCH", "value": 3}, {"label": "LPCN", "value": 4}, {"label": "BNGO", "value": 4}, {"label": "ZYXI", "value": 86}]}, "stockRatings": {"title": "Stock Ratings", "data": {"SINT": {}, "PT": {}, "GEVO": {"score": {"P/B": 3, "ROA": 2, "DCF": 3, "P/E": 3, "ROE": 2, "D/E": 3}, "recommendation": {"P/B": "Neutral", "ROA": "Neutral", "DCF": "Neutral", "P/E": "Neutral", "ROE": "Sell", "D/E": "Sell"}}, "CTRM": {}, "ATOS": {"score": {"P/B": 3, "ROA": 2, "DCF": 5, "P/E": 3, "ROE": 2, "D/E": 5}, "recommendation": {"P/B": "Neutral", "ROA": "Strong Buy", "DCF": "Strong Buy", "P/E": "Neutral", "ROE": "Sell", "D/E": "Sell"}}, "TRCH": {"score": {"P/B": 5, "ROA": 2, "DCF": 5, "P/E": 3, "ROE": 2, "D/E": 5}, "recommendation": {"P/B": "Strong Buy", "ROA": "Strong Buy", "DCF": "Strong Buy", "P/E": "Neutral", "ROE": "Sell", "D/E": "Sell"}}, "LPCN": {"score": {"P/B": 5, "ROA": 2, "DCF": 4, "P/E": 3, "ROE": 2, "D/E": 4}, "recommendation": {"P/B": "Strong Buy", "ROA": "Buy", "DCF": "Buy", "P/E": "Neutral", "ROE": "Sell", "D/E": "Sell"}}, "BNGO": {}, "ZYXI": {}}}, "enterprise": {"title": "Enterprise History", "data": {"SINT": {"symbol": "SINT", "stockPrice": 2.06, "numberOfShares": 1555988.0, "marketCapitalization": 3205335.2800000003, "minusCashAndCashEquivalents": 1787000.0, "addTotalDebt": 12000.0, "enterpriseValue": 1430335.2800000003}, "PT": {"symbol": "PT", "stockPrice": 2.51, "numberOfShares": 40304238, "marketCapitalization": 101163637.38, "minusCashAndCashEquivalents": 102755000, "addTotalDebt": 192872000, "enterpriseValue": 191280637.38}, "GEVO": {"symbol": "GEVO", "stockPrice": 1.97, "numberOfShares": 12177906, "marketCapitalization": 23990474.82, "minusCashAndCashEquivalents": 16302000, "addTotalDebt": 233000, "enterpriseValue": 7921474.82}, "CTRM": {"addTotalDebt": 14234165, "enterpriseValue": 13216195.39, "marketCapitalization": 3540969.39, "minusCashAndCashEquivalents": 4558939, "numberOfShares": 2662383, "stockPrice": 1.33, "symbol": "CTRM"}, "ATOS": {"symbol": "ATOS", "stockPrice": 1.44, "numberOfShares": 8496964.0, "marketCapitalization": 12235628.16, "minusCashAndCashEquivalents": 12581136, "addTotalDebt": 0.0, "enterpriseValue": -345507.83999999985}, "TRCH": {"symbol": "TRCH", "stockPrice": 0.62, "numberOfShares": 72857079, "marketCapitalization": 45171388.98, "minusCashAndCashEquivalents": 89730, "addTotalDebt": 11871934, "enterpriseValue": 56953592.98}, "LPCN": {"symbol": "LPCN", "stockPrice": 0.454, "numberOfShares": 25882273, "marketCapitalization": 11750551.942, "minusCashAndCashEquivalents": 9728523, "addTotalDebt": 8154448, "enterpriseValue": 10176476.942}, "BNGO": {"symbol": "BNGO", "stockPrice": 1.09, "numberOfShares": 34274469, "marketCapitalization": 37359171.21, "minusCashAndCashEquivalents": 17311373, "addTotalDebt": 0.0, "enterpriseValue": 20047798.21}, "ZYXI": {"symbol": "ZYXI", "stockPrice": 9.73, "numberOfShares": 32439000, "marketCapitalization": 315631470, "minusCashAndCashEquivalents": 14040000, "addTotalDebt": 0, "enterpriseValue": 301591470}}}, "profile": {"title": "Company Profile", "data": {"SINT": {"symbol": "SINT", "price": 2.0585, "beta": 1.58457, "volAvg": 1676117, "mktCap": 52596940, "lastDiv": 0.0, "range": "0.28-3.3", "changes": 0.2985, "companyName": "SINTX Technologies Inc", "currency": "USD", "cik": "0001269026", "isin": "US8293923079", "cusip": "829392307", "exchange": "NasdaqGS", "exchangeShortName": "NASDAQ", "industry": "Medical Devices", "website": "https://www.amedica.com/", "description": "SINTX Technologies, Inc. operates as a commercial biomaterial company. The company is headquartered in Salt Lake City, Utah and currently employs 19 full-time employees. The firm is a vertically integrated silicon nitride orthopedic medical device manufacturer. The company is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. The company is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The firm is incorporating its silicon nitride technology into components for use in total hip and knee replacement product candidates. The firm markets and sells its products to surgeons and hospitals in the United States, and certain markets in Europe and South America. The firm produces silicon nitride for use in its commercial products and product candidates in the various forms, such as solid silicon nitride, porous silicon nitride, composite silicon nitride and silicon nitride coating.", "ceo": "Dr. B. Sonny Bal", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "28", "phone": "18018393516", "address": "1885 West 2100 Street", "city": "Salt Lake City", "state": "UTAH", "zip": "84119", "dcfDiff": null, "dcf": 2.97847, "image": "https://financialmodelingprep.com/image-stock/SINT.jpg", "ipoDate": "2014-02-11", "defaultImage": true}, "PT": {"symbol": "PT", "price": 1.19, "beta": 0.0, "volAvg": 286280, "mktCap": 51334580, "lastDiv": 0.0, "range": "0.75-3.23", "changes": 0.03, "companyName": "Pintec Technology Holdings Ltd", "currency": "CNY", "cik": "0001716338", "isin": "US72352G1076", "cusip": "72352G107", "exchange": "NasdaqGM", "exchangeShortName": "NASDAQ", "industry": "Credit Services", "website": "https://www.pintec.com", "description": "Pintec Technology Holdings Ltd. engages in the provision of financial services through technology platform. The company is headquartered in Beijing, Beijing and currently employs 362 full-time employees. The firm is located in China.", "ceo": "Mr. Jun Dong", "sector": "Financial Services", "country": "CN", "fullTimeEmployees": "256", "phone": "861085643600", "address": "9/F Heng An Building, No.17 East 3Rd Ring Road", "city": "Beijing", "state": "BEIJING", "zip": null, "dcfDiff": null, "dcf": 10.1899, "image": "https://financialmodelingprep.com/image-stock/PT.png", "ipoDate": "2018-10-25", "defaultImage": false}, "GEVO": {"symbol": "GEVO", "price": 10.945, "beta": 2.79711, "volAvg": 25128327, "mktCap": 1407942910, "lastDiv": 0.0, "range": "0.46-11.68", "changes": 4.545, "companyName": "Gevo Inc", "currency": "USD", "cik": "0001392380", "isin": "US3743964062", "cusip": "374396406", "exchange": "NASDAQ Capital Market", "exchangeShortName": "NASDAQ", "industry": "Specialty Chemicals", "website": "http://www.gevo.com/", "description": "Gevo, Inc. is a renewable chemicals and next generation biofuels company, which focuses on the development and commercialization of renewable alternatives to petroleum-based products. The company is headquartered in Englewood, Colorado and currently employs 52 full-time employees. The firm has developed a technology that uses a combination of synthetic biology, metabolic engineering, chemistry and chemical engineering to focus primarily on the production of isobutanol, as well as related products from renewable feedstock. The company has two operating segments: the Gevo, Inc. segment and the Gevo Development/Agri-Energy segment. Its Gevo, Inc. segment is responsible for research and development activities related to the future production of isobutanol, including the development of its biocatalysts, the production and sale of biojet fuel, its Retrofit process and the next generation of chemicals and biofuels that will be based on its isobutanol technology. Its Gevo Development/Agri-Energy segment is responsible for the operation of its Agri-Energy Facility and the production of ethanol, isobutanol and related products.", "ceo": "Dr. Patrick Gruber", "sector": "Basic Materials", "country": "US", "fullTimeEmployees": "53", "phone": "13038588358", "address": "Building C, 345 Inverness Dr S Ste 310", "city": "Englewood", "state": "COLORADO", "zip": "80112", "dcfDiff": -11084.8, "dcf": 2.43865, "image": "https://financialmodelingprep.com/image-stock/GEVO.png", "ipoDate": "2011-02-09", "defaultImage": false}, "CTRM": {"symbol": "CTRM", "price": 0.3421, "beta": 0.0, "volAvg": 62937417, "mktCap": 124682456, "lastDiv": 0.0, "range": "0.112-2.6", "changes": 0.0065, "companyName": "Castor Maritime Inc", "currency": "USD", "cik": "0001720161", "isin": "MHY1146L1092", "cusip": "Y1146L109", "exchange": "NasdaqCM", "exchangeShortName": "NASDAQ", "industry": "Marine Shipping", "website": "http://castormaritime.com", "description": "Castor Maritime, Inc. engages in the provision of shipping transportation services through its ownership of dry bulk vessels. The firm is engaged in the ocean transportation of dry bulk cargoes worldwide through the ownership and operation of bulk carrier vessels. The company also aims to increase its fleet through acquisitions of new and modern vessels.", "ceo": "Mr. Petros Panagiotidis", "sector": "Industrials", "country": "CY", "fullTimeEmployees": "1", "phone": "35725357767", "address": "223 Christodoulou Chatzipavlou Street, Hawaii Royal Gardens", "city": "Limassol", "state": "", "zip": "3036", "dcfDiff": null, "dcf": null, "image": "https://financialmodelingprep.com/image-stock/CTRM.jpg", "ipoDate": "2018-12-20", "defaultImage": true}, "ATOS": {"symbol": "ATOS", "price": 1.4, "beta": 2.45985, "volAvg": 6160395, "mktCap": 99958320, "lastDiv": 0.0, "range": "0.76-5.08", "changes": 0.15, "companyName": "Atossa Therapeutics Inc", "currency": "USD", "cik": "0001488039", "isin": "US04962H5063", "cusip": "04962H506", "exchange": "NASDAQ Capital Market", "exchangeShortName": "NASDAQ", "industry": "Biotechnology", "website": "https://atossatherapeutics.com/", "description": "Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.", "ceo": "Dr. Steven Quay", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "4", "phone": "12065880256", "address": "107 Spring St", "city": "Seattle", "state": "WASHINGTON", "zip": "98104", "dcfDiff": -3.47, "dcf": 3.36066, "image": "https://financialmodelingprep.com/image-stock/ATOS.png", "ipoDate": "2012-11-08", "defaultImage": false}, "TRCH": {"symbol": "TRCH", "price": 1.54, "beta": 2.41048, "volAvg": 5581227, "mktCap": 153447440, "lastDiv": 0.0, "range": "0.21-1.58", "changes": 0.17, "companyName": "Torchlight Energy Resources Inc", "currency": "USD", "cik": "0001431959", "isin": "US89102U1034", "cusip": "89102U103", "exchange": "NASDAQ Capital Market", "exchangeShortName": "NASDAQ", "industry": "Oil & Gas E&P", "website": "https://www.torchlightenergy.com/", "description": "Torchlight Energy Resources, Inc. engages in the acquisition, exploration, exploitation and development of oil and natural gas properties in the United States. The company is headquartered in Plano, Texas and currently employs 2 full-time employees. The firm focuses on drilling and working interest programs within the United States. The firm has interests in approximately four oil and gas projects: the Marcelina Creek Field Development in Wilson County, Texas; the Ring Energy Joint Venture in Southwest Kansas; Hunton wells in partnership with Husky Ventures in Central Oklahoma, and the Orogrande Project in Hudspeth County, Texas. The firm also operates through two other subsidiaries, including Torchlight Energy Operating, LLC, a Texas limited liability company, and Hudspeth Oil Corporation, a Texas corporation. The Marcelina Creek Field Development is located over the Austin Chalk, Buda and Eagle Ford Formations.", "ceo": "Mr. John Brda", "sector": "Energy", "country": "US", "fullTimeEmployees": "4", "phone": "12144328002", "address": "5700 W Plano Pkwy Ste 3600", "city": "Plano", "state": "TEXAS", "zip": "75093", "dcfDiff": null, "dcf": 0.0, "image": "https://financialmodelingprep.com/image-stock/TRCH.png", "ipoDate": "2009-10-27", "defaultImage": false}, "LPCN": {"symbol": "LPCN", "price": 1.86, "beta": 0.49783, "volAvg": 2462270, "mktCap": 122176336, "lastDiv": 0.0, "range": "0.301-2.39", "changes": 0.24, "companyName": "Lipocine Inc", "currency": "USD", "cik": "0001535955", "isin": "US53630X1046", "cusip": "53630X104", "exchange": "NASDAQ Capital Market", "exchangeShortName": "NASDAQ", "industry": "Biotechnology", "website": "https://www.lipocine.com/", "description": "Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase 2b testing; LPCN 1148, an oral prodrug of bioidentical testosterone for the treatment of non-alcoholic steatohepatitis cirrhosis (NASH); LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase 2 Clinical trial for the treatment of NASH. Lipocine Inc. is headquartered in Salt Lake City, Utah.", "ceo": "Dr. Mahesh Patel", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "12", "phone": "18019947383", "address": "675 S Arapeen Dr Ste 202", "city": "Salt Lake City", "state": "UTAH", "zip": "84108", "dcfDiff": null, "dcf": 1.70588, "image": "https://financialmodelingprep.com/image-stock/LPCN.jpg", "ipoDate": "2014-03-21", "defaultImage": true}, "BNGO": {"symbol": "BNGO", "price": 9.0804, "beta": 0.0, "volAvg": 63079645, "mktCap": 2065627650, "lastDiv": 0.0, "range": "0.25-9.95", "changes": 0.6504, "companyName": "Bionano Genomics Inc", "currency": "USD", "cik": "0001411690", "isin": "US09075F1075", "cusip": "09075F107", "exchange": "NasdaqCM", "exchangeShortName": "NASDAQ", "industry": "Diagnostics & Research", "website": "https://bionanogenomics.com/", "description": "BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The company is headquartered in San Diego, California and currently employs 77 full-time employees. The firm develops and markets the Saphyr system. The Company\u2019s products include Sequencing for Discovery Research and Cytogenetics. Sequencing alone, however, is significantly limited due to its inability to reveal structural variations. Cytogenetics provide a clinical diagnosis, cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response.", "ceo": "DR. R. Erik Holmlin", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "97", "phone": "18588887600", "address": "9540 Towne Centre Dr Ste 100", "city": "San Diego", "state": "CALIFORNIA", "zip": "92121", "dcfDiff": null, "dcf": null, "image": "https://financialmodelingprep.com/image-stock/BNGO.png", "ipoDate": "2018-08-01", "defaultImage": false}, "ZYXI": {"symbol": "ZYXI", "price": 17.8029, "beta": 0.67852, "volAvg": 533546, "mktCap": 619309500, "lastDiv": 0.0, "range": "7.93-29.73", "changes": 1.2829, "companyName": "Zynex Inc", "currency": "USD", "cik": "0000846475", "isin": "US98986M1036", "cusip": "98986M103", "exchange": "NasdaqCM", "exchangeShortName": "NASDAQ", "industry": "Medical Devices", "website": "https://www.zynex.com/", "description": "Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.", "ceo": "Mr. Thomas Sandgaard", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "283", "phone": "13038673904", "address": "9555 MAROON CIRCLE", "city": "Englewood", "state": "COLORADO", "zip": "80112", "dcfDiff": null, "dcf": 14.1834, "image": "https://financialmodelingprep.com/image-stock/ZYXI.jpg", "ipoDate": "2002-11-27", "defaultImage": true}}}, "news": ["https://www.fool.com/investing/2021/01/19/why-gevo-stock-was-soaring-again-today/", "https://investorplace.com/2021/01/7-penny-stocks-that-could-see-a-surge-in-a-biden-presidency/", "https://pulse2.com/gevo-stock-price-nasdaq-gevo-increases-over-15-pre-market-why-it-happened/", "https://www.globenewswire.com/news-release/2021/01/19/2160209/0/en/Day-Five-of-Bionano-s-Next-Generation-Cytogenomics-Symposium-Saphyr-Identifies-Structural-Variants-that-May-Predispose-to-Severe-COVID-19-Illness.html", "https://www.globenewswire.com/news-release/2021/01/18/2160162/0/en/Dr-Patrick-Gruber-to-Participate-in-Water-Tower-Research-Fireside-Chat-Series-on-Thursday-January-21-2021-at-3-00-pm-EST.html"]}